Disease · MONDO_0005101
Comparisons in its trials191
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 191
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Part 1 (OLE): Etrolizumab vs Part 2 (PML SM): deaths from any cause | 9 of 1,773 | 1 of 796 | 2,569 | NCT02118584 | Trial comparisons |
| Part 1 (OLE): Etrolizumab vs Part 2 (PML SM): serious adverse events | 373 of 1,773 | 2 of 796 | 2,569 | NCT02118584 | Trial comparisons |
| Vedolizumab 300 mg (UC) vs Vedolizumab 300 mg (CD): Number of Participants With at Least One Clinically Significant Electrocardiogram (ECG) Findings | 7 of 894 | 7 of 1,349 | 2,243 | NCT00790933 | Trial comparisons |
| MMX Mesalamine/ Mesalazine (Acute Phase) vs MMX Mesalamine/ Mesalazine (Maintenance Phase): serious adverse events | 13 of 717 | 14 of 461 | 1,178 | NCT01124149 | Trial comparisons |
| Mesalamine Once-Daily vs Mesalamine Twice-Daily: Number of Subjects Who Relapse/Flare Within 6 Months, ITT Population | 45 of 512 | 39 of 511 | 1,023 | NCT00505778 | Trial comparisons |
| Mesalamine Once-Daily vs Mesalamine Twice-Daily: serious adverse events | 18 of 512 | 9 of 511 | 1,023 | NCT00505778 | Trial comparisons |
| Tofacitinib 5 mg BID vs Tofacitinib 10 mg BID: Number of Participants With Serious Infections as Treatment Emergent Adverse Events (TEAEs) | 8 of 175 | 31 of 769 | 944 | NCT01470612 | Trial comparisons |
| Tofacitinib 5 mg BID vs Tofacitinib 10 mg BID: deaths from any cause | 0 of 175 | 6 of 769 | 944 | NCT01470612 | Trial comparisons |
| Tofacitinib 5 mg BID vs Tofacitinib 10 mg BID: Number of Participants With Clinically Significant Changes in Physical Examinations From Baseline | 84 of 175 | 391 of 769 | 944 | NCT01470612 | Trial comparisons |
| Tofacitinib 5 mg BID vs Tofacitinib 10 mg BID: serious adverse events | 39 of 175 | 147 of 769 | 944 | NCT01470612 | Trial comparisons |
| Tofacitinib 5 mg BID vs Tofacitinib 10 mg BID: Number of Participants With Laboratory Test Abnormalities | 162 of 175 | 670 of 761 | 936 | NCT01470612 | Trial comparisons |
| SPD476 vs Asacol: serious adverse events | 6 of 415 | 3 of 411 | 826 | NCT00151892 | Trial comparisons |
| TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG): Period 1: Rectal Bleeding Sub-score of 0 | 212 of 388 | 226 of 386 | 774 | NCT01903252 | Trial comparisons |
| TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG): Period 1: Clinical Remission at Both Week 8 and 12 | 66 of 388 | 80 of 386 | 774 | NCT01903252 | Trial comparisons |
| TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG): Period 1: Clinical Remission | 92 of 388 | 110 of 386 | 774 | NCT01903252 | Trial comparisons |
| TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG): Period 1: Clinical and Endoscopic Remission | 87 of 388 | 95 of 386 | 774 | NCT01903252 | Trial comparisons |
| TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG): Period 1: Clinical Response | 223 of 388 | 233 of 386 | 774 | NCT01903252 | Trial comparisons |
| TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG): Period 1: Clinical Response at Both Week 8 and Week 12 | 216 of 388 | 230 of 386 | 774 | NCT01903252 | Trial comparisons |
| TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG): Period 1: Clinical Remission | 93 of 388 | 113 of 386 | 774 | NCT01903252 | Trial comparisons |
| TP05 (Mesalazine) vs Asacol (Mesalazine, Tillotts Pharma AG): Period 1: Endoscopic Response | 185 of 388 | 196 of 386 | 774 | NCT01903252 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005101/comparisons